Ravi Vij, MD | Authors

SOUTHLAKE REGIONAL HEALTH CENT

596 DAVIS DRIVE

C/O PROFESSIONAL PRACTICE

Articles

Treatment-Related Adverse Events in Patients With Relapsed/Refractory Multiple Myeloma

November 15, 2011

The rational development of novel targeted therapies is expanding treatment options for patients with relapsed/refractory (R/R) multiple myeloma (MM). The first-in-class proteasome inhibitor (PI) bortezomib (Velcade), the immunomodulatory agents thalidomide (Thalomid) and lenalidomide (Revlimid), and liposomal doxorubicin are currently the major approved therapeutic agents in this setting.[1]